Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2014-05-09

FDA Approved: ATROVENT HFA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ATROVENT HFA (ipratropium bromide) from Boehringer Ingelheim Pharmaceuticals, Inc., reflecting changes to the pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ATROVENT HFA (IPRATROPIUM BROMIDE)

Snippet

SUPPL AP for ATROVENT HFA (IPRATROPIUM BROMIDE)